A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in ...

The company behind the test said there were positive signs that some of the most aggressive cancers could be prevented.

Grail said Galleri, its multi-cancer early detection test, failed to meet the primary endpoint of a recent trial. The stock slid 47%, to $54.20, in after-hours trading. Through market close, share ...

Grail’s shares plummeted more than 45% after-hours Thursday as the medtech revealed a major National Health Service (NHS) ...

Grail's blood test for detecting cancer early failed to meet its main goal in a giant study being conducted with England’s ...

By Kamal Choudhury and Mariam Sunny Feb 20 (Reuters) - Grail's shares plunged nearly 50% on Friday after the company said routine screening with its cancer blood test failed to significantly boost ...

GRAIL, however, highlighted a favorable trend toward fewer Stage III-IV cancers in a pre-specified group of 12 deadly cancers ...

Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in stage III and IV cancers.

Men’s Health Network debuts “My Cancer, My Plan” Podcast to help men navigate diagnosis, treatment decisions, and ...

Disney alum Christy Carlson Romano is getting candid about a frightening new health scare. The “Even Stevens” star revealed ...

"Even Stevens" and "Kim Possible" star Christy Carlson Romano took to Instagram on Tuesday to share that she recently tested ...